These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 24070541)

  • 1. The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis.
    O'Dwyer DN; Armstrong ME; Trujillo G; Cooke G; Keane MP; Fallon PG; Simpson AJ; Millar AB; McGrath EE; Whyte MK; Hirani N; Hogaboam CM; Donnelly SC
    Am J Respir Crit Care Med; 2013 Dec; 188(12):1442-50. PubMed ID: 24070541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candidate Role for Toll-like Receptor 3 L412F Polymorphism and Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
    McElroy AN; Invernizzi R; Laskowska JW; O'Neill A; Doroudian M; Moghoofei M; Mostafaei S; Li F; Przybylski AA; O'Dwyer DN; Bowie AG; Fallon PG; Maher TM; Hogaboam CM; Molyneaux PL; Hirani N; Armstrong ME; Donnelly SC
    Am J Respir Crit Care Med; 2022 Mar; 205(5):550-562. PubMed ID: 34985402
    [No Abstract]   [Full Text] [Related]  

  • 3. Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosis.
    Cooke G; Kamal I; Strengert M; Hams E; Mawhinney L; Tynan A; O'Reilly C; O'Dwyer DN; Kunkel SL; Knaus UG; Shields DC; Moller DR; Bowie AG; Fallon PG; Hogaboam CM; Armstrong ME; Donnelly SC
    QJM; 2018 Apr; 111(4):217-224. PubMed ID: 29237089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of TLR3 L412F Polymorphism with Cytomegalovirus Infection in Children.
    Studzińska M; Jabłońska A; Wiśniewska-Ligier M; Nowakowska D; Gaj Z; Leśnikowski ZJ; Woźniakowska-Gęsicka T; Wilczyński J; Paradowska E
    PLoS One; 2017; 12(1):e0169420. PubMed ID: 28046022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein Tyrosine Phosphatase-N13 Promotes Myofibroblast Resistance to Apoptosis in Idiopathic Pulmonary Fibrosis.
    Bamberg A; Redente EF; Groshong SD; Tuder RM; Cool CD; Keith RC; Edelman BL; Black BP; Cosgrove GP; Wynes MW; Curran-Everett D; De Langhe S; Ortiz LA; Thorburn A; Riches DWH
    Am J Respir Crit Care Med; 2018 Oct; 198(7):914-927. PubMed ID: 29727583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biological significance of TLR3 variant, L412F, in conferring susceptibility to cutaneous candidiasis, CMV and autoimmunity.
    Nahum A; Dadi H; Bates A; Roifman CM
    Autoimmun Rev; 2012 Mar; 11(5):341-7. PubMed ID: 22024499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activator inhibitor-1 suppresses profibrotic responses in fibroblasts from fibrotic lungs.
    Marudamuthu AS; Shetty SK; Bhandary YP; Karandashova S; Thompson M; Sathish V; Florova G; Hogan TB; Pabelick CM; Prakash YS; Tsukasaki Y; Fu J; Ikebe M; Idell S; Shetty S
    J Biol Chem; 2015 Apr; 290(15):9428-41. PubMed ID: 25648892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis.
    Samara KD; Antoniou KM; Karagiannis K; Margaritopoulos G; Lasithiotaki I; Koutala E; Siafakas NM
    Int J Oncol; 2012 May; 40(5):1397-404. PubMed ID: 22344343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis.
    O'Dwyer DN; Armstrong ME; Kooblall M; Donnelly SC
    Expert Opin Ther Targets; 2015 Apr; 19(4):507-14. PubMed ID: 25530171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
    Araki K; Kinoshita R; Tomonobu N; Gohara Y; Tomida S; Takahashi Y; Senoo S; Taniguchi A; Itano J; Yamamoto KI; Murata H; Suzawa K; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Ichimura K; Nishibori M; Miyahara N; Toyooka S; Sakaguchi M
    J Mol Med (Berl); 2021 Jan; 99(1):131-145. PubMed ID: 33169236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF.
    Ebener S; Barnowski S; Wotzkow C; Marti TM; Lopez-Rodriguez E; Crestani B; Blank F; Schmid RA; Geiser T; Funke M
    Am J Physiol Lung Cell Mol Physiol; 2017 Jan; 312(1):L42-L55. PubMed ID: 27815256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipocalin-2 as a prognostic marker in patients with acute exacerbation of idiopathic pulmonary fibrosis.
    Tanahashi H; Iwamoto H; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Nakashima T; Ohshimo S; Fujitaka K; Hamada H; Hattori N
    Respir Res; 2024 May; 25(1):195. PubMed ID: 38704585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis.
    Molyneaux PL; Cox MJ; Willis-Owen SA; Mallia P; Russell KE; Russell AM; Murphy E; Johnston SL; Schwartz DA; Wells AU; Cookson WO; Maher TM; Moffatt MF
    Am J Respir Crit Care Med; 2014 Oct; 190(8):906-13. PubMed ID: 25184687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
    Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PGC1α repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state.
    Caporarello N; Meridew JA; Jones DL; Tan Q; Haak AJ; Choi KM; Manlove LJ; Prakash YS; Tschumperlin DJ; Ligresti G
    Thorax; 2019 Aug; 74(8):749-760. PubMed ID: 31182654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between a functional polymorphism in Toll-like receptor 3 and chronic hepatitis C in liver transplant recipients.
    Lee SO; Brown RA; Razonable RR
    Transpl Infect Dis; 2013 Apr; 15(2):111-9. PubMed ID: 23240626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis.
    Naik PK; Bozyk PD; Bentley JK; Popova AP; Birch CM; Wilke CA; Fry CD; White ES; Sisson TH; Tayob N; Carnemolla B; Orecchia P; Flaherty KR; Hershenson MB; Murray S; Martinez FJ; Moore BB;
    Am J Physiol Lung Cell Mol Physiol; 2012 Dec; 303(12):L1046-56. PubMed ID: 23043074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality.
    Tsitoura E; Trachalaki A; Vasarmidi E; Mastrodemou S; Margaritopoulos GA; Kokosi M; Fanidis D; Galaris A; Aidinis V; Renzoni E; Tzanakis N; Wells AU; Antoniou KM
    Front Immunol; 2021; 12():645548. PubMed ID: 34867934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
    Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
    PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis.
    Peljto AL; Zhang Y; Fingerlin TE; Ma SF; Garcia JG; Richards TJ; Silveira LJ; Lindell KO; Steele MP; Loyd JE; Gibson KF; Seibold MA; Brown KK; Talbert JL; Markin C; Kossen K; Seiwert SD; Murphy E; Noth I; Schwarz MI; Kaminski N; Schwartz DA
    JAMA; 2013 Jun; 309(21):2232-9. PubMed ID: 23695349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.